Abstract 181P
Background
Leiomyosarcoma (LMS) is a highly aggressive and rare malignancy, often presenting as large tumors with potentially heterogeneous tumor microenvironment (TME). This TME heterogeneity may contribute to poor responsiveness to immunotherapy and its overall unfavorable prognosis. We aimed to provide a detailed characterization of the intratumoral heterogeneity and possible mechanisms of non-responsiveness to immune checkpoint inhibitors in large LMS.
Methods
We investigated four large treatment-naïve LMS (ten samples/tumor). We analyzed four regions: vital and necrotic centers (VC, NC), organ-adjacent and free margins (O-AM, FM), where we evaluated T cells, macrophages, immune inhibitory molecules, and tertiary lymphoid structures (TLS) by IHC and flow cytometry. Moreover, we performed unsupervised clustering of flow cytometry data and analyzed cytokine secretion after anti-LAG-3 blockade in each tumor sample. Lastly, factorial analysis of mixed data (FAMD) analysis revealed the drivers of tumor sample variability.
Results
The expression of PD-1 and PD-L1 profoundly varied within the same tumor tissue. TLS were detected only at the tumor margins. Interestingly, TLS were present in one out of ten samples in one LMS tissue. Moreover, shared immune patterns were detected in specific tumor regions, such as higher levels of IDO, absence of specific macrophage subpopulation, and lower levels of PD-1 and LAG-3 expression in the O-AM. Following the findings about LAG-3 expression, we tested the cell's reactivity to anti-LAG-3 blockade. This blockade enhanced IL-8 in the NC and PD-L1 in the O-AM compared to other tumor regions. FAMD showed that samples can be separated by the tumor regions, where VC and NC displayed distinct patterns.
Conclusions
Our findings emphasize the importance of multiple biopsies to accurately assess the immune heterogeneity in large LMS. The intratumoral heterogeneity may explain varied responses to immunotherapy, even with low or absent expression of these molecules. A single biopsy may not capture the full spectrum of immune cell infiltration, potentially leading to incomplete evaluations. Advanced immunoprofiling offers deeper insights into the TME, improving diagnostic accuracy and treatment selection. AZV NU23J-08–00031, GA UK 94323.
Legal entity responsible for the study
University Hospital Motol, Prague, Czech Republic.
Funding
Czech Health Research Council NU23J-08-0031, Charles University in Prague - 94323.
Disclosure
J. Bartunkova: Financial Interests, Personal, Full or part-time Employment and a minority shareholder: Sotio Biotech, a.s. All other authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract